#1 Clinical Trials Search in Europe

(S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Several clinical trials are investigating the use of 68Ga-FAPI-46, a novel PET imaging agent, for diagnosing and staging various types of cancer. These studies aim to evaluate the diagnostic accuracy and potential benefits of 68Ga-FAPI-46 PET/CT scans compared to standard imaging techniques like FDG PET/CT. The trials focus on cancers such as breast cancer, gastroesophageal cancer, pancreatic cancer, and ovarian cancer. Researchers hope to determine if 68Ga-FAPI-46 PET/CT can improve cancer detection, staging accuracy, and treatment planning for patients.

Table of Contents

Introduction

Cancer diagnosis and monitoring have seen significant advancements in recent years, with new imaging techniques playing a crucial role. One such promising development is the use of 68Ga-FAPI-46, a novel imaging agent that is currently being studied for its potential to improve cancer detection and staging[1].

What is 68Ga-FAPI-46?

68Ga-FAPI-46 is a radioactive tracer used in Positron Emission Tomography (PET) scans. Its full chemical name is (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE[2]. It’s also known by the shorter name 68Ga-FAPI, where FAPI stands for Fibroblast Activation Protein Inhibitor.

How it Works

68Ga-FAPI-46 works by targeting a protein called Fibroblast Activation Protein (FAP). This protein is found in high amounts in the supporting tissue of many types of tumors, but not in most normal tissues. When injected into the body, 68Ga-FAPI-46 attaches to FAP in cancer tissues. The radioactive element (68Ga) then emits signals that can be detected by a PET scanner, creating detailed images of where cancer might be present in the body[2].

Potential Benefits

Researchers are excited about 68Ga-FAPI-46 because it may offer several advantages over current imaging techniques:

  • Improved detection: It may be able to detect cancer lesions that are difficult to see with other imaging methods[3].
  • Better staging: It could help doctors more accurately determine how far a cancer has spread, which is crucial for planning treatment[4].
  • Monitoring treatment: It might be useful for checking how well cancer treatments are working[5].
  • Faster imaging: The scan can be done quickly after injection, potentially making the process more comfortable for patients[3].

Current Research

Several clinical trials are currently underway to study the effectiveness of 68Ga-FAPI-46 in different types of cancer:

  • Breast Cancer: A study called “SKYLINE” is looking at how well 68Ga-FAPI-46 PET/CT scans can detect triple-negative breast cancer, both in early stages and when it has spread[1].
  • Gastric and Esophageal Cancer: Researchers are comparing 68Ga-FAPI-46 PET/CT to standard imaging methods for diagnosing and staging cancers of the stomach and esophagus[5].
  • Pancreatic Cancer: A study called “BEFAST” is investigating how 68Ga-FAPI-46 PET/CT performs in detecting pancreatic cancer[3].
  • Ovarian Cancer: Another trial is examining the accuracy of 68Ga-FAPI-46 PET/CT in diagnosing and staging ovarian cancer[6].

Safety and Side Effects

While 68Ga-FAPI-46 is still being studied, early results suggest it is generally well-tolerated. As with any medical procedure involving radiation, there are some risks, but these are typically very low. The amount of radiation used in a PET scan is small and leaves the body quickly[4].

Some studies are specifically monitoring for any side effects or allergic reactions. Patients are typically observed for a short time after the injection, and vital signs like heart rate and blood pressure are checked[6].

Conclusion

68Ga-FAPI-46 is a promising new tool in the fight against cancer. While it’s still in the research phase, early results are encouraging. If proven effective, it could significantly improve how doctors detect, stage, and monitor various types of cancer. As with any medical advancement, more research is needed to fully understand its benefits and potential risks. Patients interested in this new imaging technique should discuss it with their healthcare providers to see if participating in a clinical trial might be appropriate for their situation.

Aspect Details
Main objective Evaluate diagnostic accuracy of 68Ga-FAPI-46 PET/CT compared to standard imaging for cancer detection and staging
Cancer types studied Breast cancer, gastroesophageal cancer, pancreatic cancer, ovarian cancer
Key comparisons 68Ga-FAPI-46 PET/CT vs FDG PET/CT for lesion detection, staging accuracy, and treatment response assessment
Potential benefits Improved cancer detection, more accurate staging, better treatment planning, earlier detection of relapse
Safety considerations Monitoring for adverse reactions, vital sign checks before and after scans
Additional analyses Correlation of imaging results with pathology, investigation of unexpected findings, interobserver agreement studies

FAQ

  • What is 68Ga-FAPI-46? 68Ga-FAPI-46 is a novel radioactive tracer used in PET/CT imaging. It targets fibroblast activation protein (FAP), which is often present in cancer-associated fibroblasts. This allows it to potentially detect certain types of cancers and their spread in the body.
  • What types of cancer are being studied with 68Ga-FAPI-46 PET/CT? The clinical trials are investigating 68Ga-FAPI-46 PET/CT for several cancer types, including breast cancer, gastroesophageal cancer (cancer of the stomach and esophagus junction), pancreatic cancer, and ovarian cancer.
  • How does 68Ga-FAPI-46 PET/CT compare to standard imaging techniques? The trials aim to compare 68Ga-FAPI-46 PET/CT to standard imaging techniques like FDG PET/CT. Researchers are evaluating if 68Ga-FAPI-46 PET/CT can provide better diagnostic accuracy, improved cancer staging, and more precise detection of tumor spread.
  • What are the potential benefits of using 68Ga-FAPI-46 PET/CT? Potential benefits being studied include improved cancer detection, more accurate staging, better treatment planning, and the ability to monitor treatment response. Some trials are also looking at whether 68Ga-FAPI-46 PET/CT can detect cancer earlier or in cases where standard techniques may not be as effective.
  • Are there any risks associated with 68Ga-FAPI-46 PET/CT scans? As with any medical procedure involving radiation, there are potential risks. The trials are monitoring for any side effects or adverse reactions to the 68Ga-FAPI-46 tracer. Patients are carefully screened for eligibility, and the studies include safety monitoring such as checking vital signs before and after the scan.

Ongoing Clinical Trials on (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • PET/CT: Positron Emission Tomography/Computed Tomography, an imaging technique that combines PET and CT scans to provide detailed pictures of structures inside the body and their function.
  • 68Ga-FAPI-46: A radioactive tracer used in PET imaging that targets fibroblast activation protein (FAP), which is often present in cancer-associated cells.
  • FDG PET/CT: A standard imaging technique using fluorodeoxyglucose (FDG) as a tracer to detect areas of high glucose metabolism, often associated with cancer cells.
  • Neoadjuvant chemotherapy: Chemotherapy given before surgery to shrink tumors and make them easier to remove.
  • Staging: The process of determining the extent and spread of cancer in the body, which helps guide treatment decisions.
  • Metastasis: The spread of cancer from its original site to other parts of the body.
  • SUV: Standardized Uptake Value, a measure of how much radiotracer is taken up by tissue in PET imaging.
  • TBR: Tumor-to-Background Ratio, a measure comparing the uptake of a tracer in tumor tissue to normal tissue.
  • MTV: Metabolic Tumor Volume, a measure of the volume of metabolically active tumor in PET imaging.
  • TLG: Total Lesion Glycolysis, a measure combining the volume and intensity of glucose uptake in tumors on PET scans.

References

  1. http://clinicaltrials.eu/trial/study-on-tiragolumab-atezolizumab-and-chemotherapy-for-patients-with-early-and-metastatic-triple-negative-breast-cancer/
  2. http://clinicaltrials.eu/trial/study-on-early-detection-of-triple-negative-breast-cancer-relapse-using-68ga-fapi-46-for-patients-at-high-risk/
  3. http://clinicaltrials.eu/trial/study-on-68gaga-fapi-46-pet-ct-imaging-for-better-diagnosis-in-patients-with-pancreatic-and-gastroesophageal-cancer/
  4. http://clinicaltrials.eu/trial/study-on-68gaga-fapi-46-and-iodixanol-for-better-imaging-in-patients-with-pancreatic-and-gastroesophageal-cancer/
  5. http://clinicaltrials.eu/trial/study-on-68ga-fapi-46-and-fludeoxyglucose-18f-for-diagnosing-stomach-and-gastroesophageal-junction-cancer-in-patients-undergoing-chemotherapy/
  6. http://clinicaltrials.eu/trial/study-on-the-accuracy-of-68ga-fapi-46-and-fludeoxyglucose-18f-pet-ct-scans-for-staging-and-restaging-in-patients-with-ovarian-cancer/